Has Angela Traylor, MD received payments from drug or device companies?

Yes. Drug and device makers reported $561 in general payments to Angela Traylor, MD across 16 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Angela Traylor, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Angela Traylor, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Angela Traylor, MD

Neurology · New Orleans, LANPI 1427028844

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $199, more than ten times the $15 reported in 2019. That places this record below the midpoint for neurology clinicians in LA, where the typical reported total is $2,263.

$561in general payments, 2019–2025

Across 16 payments — averaging $35.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

UCB, Inc.$120
AstraZeneca$115
F. Hoffmann-la Roche AG$80
Eisai Inc.$65
Otsuka America Pharmaceutical, Inc.$57
Amgen$35
plus $89 from 4 others

$940,900in research payments, 2019–2025

Across 64 payments — averaging $14,702 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$558K
Janssen Research & Development, LLC$165K
E.r. Squibb & Sons, L.L.C.$88K
AbbVie$59K
Bioxcel Therapeutics, Inc.$45K
Otsuka Pharmaceutical Development & Commercialization, Inc.$19K
plus $8K from 2 others

What the payments were for

Food & beverage$561100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
UCB, Inc.	2	$120
AstraZeneca	1	$115
F. Hoffmann-la Roche AG	1	$80
Eisai Inc.	2	$65
Otsuka America Pharmaceutical, Inc.	3	$57
Amgen	2	$35
Pfizer	2	$33
Sunovion Pharmaceuticals Inc.	1	$23
Lundbeck LLC	1	$21
Biohaven Pharmaceutical Holding Company Ltd.	1	$12

How this compares

$561 in reported general payments places this provider in the 25th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana →

Medicare billing

Part B allowed, 2024

$3,441

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Metyrosine	12	$174,798
Invega SustennaPaliperidone Palmitate	15	$27,413
Lisdexamfetamine Dimesylate	13	$3,909
Oxcarbazepine	41	$2,751
Wellbutrin SrBupropion Hcl	13	$2,697
Memantine Hcl	74	$2,677
Zolpidem Tartrate	30	$2,662
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine	86	$2,514
Lamotrigine ErLamotrigine	13	$1,747
Aripiprazole	52	$1,583
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine	26	$1,425
Bupropion XlBupropion Hcl	63	$1,243
Duloxetine Hcl	117	$968
Gabapentin	65	$938
Lamotrigine	51	$919

Paid to pharmacies, not to this prescriber.

Other neurology in New Orleans

John EnglandNew Orleans$268K
Brian CopelandNew Orleans$211K
Bridget BagertNew Orleans$198K
Sheryl Martin-SchildNew Orleans$106K
Piotr OlejniczakNew Orleans$82K
Elizabeth CrabtreeNew Orleans$36K
Caroline GoldinNew Orleans$36K
Jesus LoveraNew Orleans$27K
Julia StaischNew Orleans$22K
Pooja Mohan RaoNew Orleans$17K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →